IMPEDIMED LIMITED (IPD)
Share Price Analysis and Chart

Enter the company code or Name for stock analysis:

IPD

IPD - IMPEDIMED LIMITED

FNArena Sector : Medical Equipment & Devices
Year End: June
GICS Industry Group : Health Care Equipment & Services
Debt/EBITDA: -0.74
Index:

LAST PRICE CHANGE +/- CHANGE % VOLUME

$0.036

16 Sep
2025

-0.003

OPEN

$0.04

-7.69%

HIGH

$0.04

1,032,670

LOW

$0.04

TARGET
$0.13 261.1% upside
OTHER COMPANIES IN THE SAME SECTOR
4DX . AT1 . AYA . BB1 . BRN . CAT . CBL . CGS . CMP . COH . CSX . CU6 . CVB . CYC . EBR . EMV . EYE . FPH . IME . IMR . LDX . MX1 . NAN . ONE . PCK . PEB . PGC . PME . RMD . SOM . TRJ . UBI .
FNARENA'S MARKET CONSENSUS FORECASTS
IPD: 1
Title FY24
Actual		 FY25
Actual		 FY26
Forecast		 FY27
Forecast
EPS (cps) xxx - 1.2 - 0.7 xxx
DPS (cps) xxx 0.0 0.0 xxx
EPS Growth xxx N/A N/A xxx
DPS Growth xxx N/A N/A xxx
PE Ratio xxx N/A N/A xxx
Dividend Yield xxx N/A 0.0% xxx
Div Pay Ratio(%) xxx N/A N/A xxx

Dividend yield today if purchased 3 years ago: 0.00%

DIVIDEND YIELD CALCULATOR

Dividend Yield Today On Last Actual Payout :

 0.00

Estimated Dividend Growth
(Average Of Past Three Years)

  %

Amount Invested

 $ 

Tell Me The Dividend After This Many Years
Past performance is no guarantee for the future. Investors should take into account that heavy swings in share price or exceptional circumstances (a la 2009) can have a significant impact on short term calculations and averages
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2025 FactSet UK Limited. All rights reserved
Title 202020212022202320242025
EPS Basic xxxxxxxxxxxxxxx-1.2
DPS All xxxxxxxxxxxxxxx0.0
Sales/Revenue xxxxxxxxxxxxxxx12.7 M
Book Value Per Share xxxxxxxxxxxxxxx1.0
Net Operating Cash Flow xxxxxxxxxxxxxxx-15.2 M
Net Profit Margin xxxxxxxxxxxxxxx-182.62 %

EPS Basic

DPS All

Sales/Revenue

Book Value Per Share

Net Operating Cash Flow

Net Profit Margin

Title 202020212022202320242025
Return on Capital Employed xxxxxxxxxxxxxxx-75.89 %
Return on Invested Capital xxxxxxxxxxxxxxx-60.93 %
Return on Assets xxxxxxxxxxxxxxx-52.43 %
Return on Equity xxxxxxxxxxxxxxx-75.89 %
Return on Total Capital xxxxxxxxxxxxxxx-62.98 %
Free Cash Flow ex dividends xxxxxxxxxxxxxxx-15.3 M

Return on Capital Employed

Return on Invested Capital

Return on Assets

Return on Equity

Return on Total Capital

Free Cash Flow ex dividends

Title 202020212022202320242025
Short-Term Debt xxxxxxxxxxxxxxx0 M
Long Term Debt xxxxxxxxxxxxxxx14 M
Total Debt xxxxxxxxxxxxxxx14 M
Goodwill - Gross xxxxxxxxxxxxxxx3 M
Cash & Equivalents - Generic xxxxxxxxxxxxxxx22 M
Price To Book Value xxxxxxxxxxxxxxx3.46

Short-Term Debt

Long Term Debt

Total Debt

Goodwill - Gross

Cash & Equivalents - Generic

Price To Book Value

Title 202020212022202320242025
Capex xxxxxxxxxxxxxxx1.0 M
Capex % of Sales xxxxxxxxxxxxxxx7.77 %
Cost of Goods Sold xxxxxxxxxxxxxxx28 M
Selling, General & Admin. Exp & Other xxxxxxxxxxxxxxx9 M
Research & Development xxxxxxxxxxxxxxx0 M
Investments - Total xxxxxxxxxxxxxxx0 M

Capex

Capex % of Sales

Cost of Goods Sold

Selling, General & Admin. Exp & Other

Research & Development

Investments - Total

EXPERT VIEWS
Display All Commentary

Sentiment Indicator

1.0

No. Of Recommendations

2
BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Morgans

xx/xx/xxxx

1

xxxxxxxxxxx xxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Ord Minnett

01/08/2025

1

Speculative Buy

$0.12

233.33%

ImpediMed announced its 4Q25 result, which showed improving momentum across its businesses, according to Ord Minnett.

US Sozo sales rose 100% on the prior quarter to 44, with record total contract value of $6.3m.

The pipeline stands at 699 Sozos, a rise of 25% on the third quarter, with 36 US states now over 80%, and the company is considering expansion into the body composition market, the analyst explains.

Speculative Buy rating retained. Target remains at 12c.

FORECAST
Ord Minnett forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -0.60 cents.
Access Stockbroker Research History >
EXTRA COVERAGE
Display All Commentary

No. Of Recommendations

2

Please note: unlike Broker Call Report, BC Extra is not updated daily. The info you see might not be the latest. FNArena does its best to update ASAP.

BROKER DATE RATING RECOMMENDATION TARGET PRICE % TO REACH TARGET COMMENTARY

Wilsons

xx/xx/xxxx

1

xxxxxxxxxx

$xx.xx

xx.xx%

Broker commentary and detailed analysis is available for Full Members Only.
Login above or Get a Free Trial

Canaccord Genuity

05/05/2025

1

Speculative Buy

$0.09

150.00%

ImpediMed reported record revenue of $3.4m, up from $3.3m in 2Q25, with 36 Sozo units sold, although international unit sales declined, Canaccord Genuity explains. Annual recurring revenue increased to $13.7m, up 10% quarter-on-quarter.

Despite clinical and reimbursement milestones, such as 258m lives covered in the US, the broker remains disappointed with the conversion of market access into revenue.

Sales team deficiencies were acknowledged, and a new SVP of Sales was appointed during the quarter.  The company announced a rise in cash burn due to higher advertising and inventory build. The balance sheet was strengthened by a $10m drawdown from a capital facility, lifting cash to $27.9m.

Canaccord flags weak commercial execution as the key issue, noting its $15.3m FY25 revenue forecast may be optimistic. 

Speculative Buy rating on ImpediMed and a $0.09 target price retained.

FORECAST
Canaccord Genuity forecasts a full year FY26 dividend of 0.00 cents and EPS of minus -1.00 cents.
Access Extra Coverage Research History >

IPD STOCK CHART

FNArena News on IPD

1
Australian Broker Call *Extra* Edition – Sep 08, 2025

Sep 08 2025 - Daily Market Reports
2
FNArena Corporate Results Monitor – 29-08-2025

Aug 29 2025 - Australia
3
Australian Broker Call *Extra* Edition – May 05, 2025

May 05 2025 - Daily Market Reports
4
FNArena Corporate Results Monitor – 05-03-2025

Mar 05 2025 - Australia
5
Rudi’s View: Earnings Optimism On The Rise

Feb 05 2025 - Rudi's View

Latest Medical Equipment & Devices News

1
Cochlear’s Future In Nexa’s Hands

Aug 19 2025 - Australia
2
ResMed’s New Level Of Support

Jul 29 2025 - Technicals
3
Strength To ‘AI’ Strength For Pro Medicus

Jul 10 2025 - Australia
4
Cochlear Downgrades Ahead Of New Launches

Jun 19 2025 - Australia
5
Fisher & Paykel Healthcare’s Tariffs Annoyance

Jun 04 2025 - Australia
6
ResMed’s Margin Expansion & Tariff Exemption

Apr 28 2025 - Australia
7
Trend Remains Up For Catapult International

Feb 18 2025 - Technicals
8
ESG Focus: Top ASX Companies, Superbugs & Hydrogen

Feb 07 2025 - ESG Focus
9
ResMed Shakes Off GLP-1 Scare

Feb 04 2025 - Australia
10
ResMed: Another Positive Quarterly Surprise?

Jan 30 2025 - Australia